VVUS positive AdCom vote. Pipeline updates for SNTA AMLN DYAX + HZNP AVII news

Feb 23, 2012 No Comments by

VIVUS, Inc. (NASDAQ: VVUS) today announced that the Endocrinologic and Metabolic Drugs Advisory Committee recommended Qnexa be granted marketing approval by the FDA for the treatment of obesity in adults. The Committee voted in favour by 20 to 2. The PDUFA date for Qnexa is April 17, 2012.

Synta Pharmaceuticals Corp. (NASDAQ: SNTA) provided a pipeline update noting that it expects to complete enrolment in the Phase 2b portion of its Phase 2b/3 trial of ganetespib in combination with docetaxel vs. docetaxel alone in patients with advanced NSCLC, in 2Q 2012 (GALAXY trial), with interim Phase 2b results also in 2Q. Final PFS data and preliminary OS data from the Phase 2b portion are expected in 2H 2012 and initiation of the Phase 3 portion expected during 2H 2012.

Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) said in its annual report that it intends to submit the chemistry, manufacturing and controls section of the metreleptin BLA to treat diabetes and/or hypertriglyceridemia in pediatric and adult patients with inherited or acquired lipodystrophy, during  1H 2012. It intends to apply for fast-track and priority-review designation, which, if granted, could translate to a PDUFA action date by the end of 2012.

Horizon Pharma, Inc. (NASDAQ: HZNP) announced today that it has entered into a loan agreement with a group of lenders to provide $60 million in capital.

AVI BioPharma, Inc. (NASDAQ: AVII) announced it regained compliance with NASDAQ’s minimum $1.00 per share bid price requirement.

Dyax Corp. (NASDAQ: DYAX) gave a pipeline update today noting that data from its Phase 2 trial of ecallantide in angiotensin converting enzyme (ACE) inhibitor-induced angioedema, are due during 2H 2012.

Daily News

About the author

Currently residing in New Zealand and employed in the education industry, Mr. A. Burden holds a M.Com in International Business from the University of Sydney and used these skills together with his passion for investing to establish BioPharmCatalyst in June 2010 as a tool for investing decisions in the US pharmaceutical market. He spends much of his free time mountain biking, playing squash and hiking.
No Responses to “VVUS positive AdCom vote. Pipeline updates for SNTA AMLN DYAX + HZNP AVII news”

Leave a Reply